| Identification | Back Directory | [Name]
1H-Benzimidazole-6-carboxylic acid, 2-[[4-[(2S)-2-(5-chloro-2-pyridinyl)-2-methyl-1,3-benzodioxol-4-yl]-1-piperidinyl]methyl]-1-[(2S)-2-oxetanylmethyl]- | [CAS]
2401892-75-7 | [Synonyms]
2-[[4-[(2S)-2-(5-chloro-2-pyridinyl)-2-methyl-1,3-benzodioxol-4-yl]-1-piperidinyl]methyl]-1-[(2S)-2-oxetanylmethyl
1H-Benzimidazole-6-carboxylic acid, 2-[[4-[(2S)-2-(5-chloro-2-pyridinyl)-2-methyl-1,3-benzodioxol-4-yl]-1-piperidinyl]methyl]-1-[(2S)-2-oxetanylmethyl]-
2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo(d][1,3]dioxol-4-yl)piperidin-1 -yl)methyl)-1 -(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid | [Molecular Formula]
C31H31ClN4O5 | [MOL File]
2401892-75-7.mol | [Molecular Weight]
575.05 |
| Chemical Properties | Back Directory | [Boiling point ]
752.9±60.0 °C(Predicted) | [density ]
1.47±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
7.82±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM)[1]. | [References]
[1] Buckeridge C, et al. Once-daily oral small molecule GLP-1R agonist PF-07081532 reduces glucose and body weight within 4-6 weeks in adults with type 2 diabetes and non-diabetic adults with obesity. Hybrid 58th EASD Annual Meeting; Sept 19–23, 2022 (abstr 114).
[2] Sloop KW, et al., The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med. 2024 Dec 18;16(778):eadp5765. DOI:10.1126/scitranslmed.adp5765 |
|
| Company Name: |
RuiKeXin
|
| Tel: |
19938953786 |
| Website: |
ahreaction.com/ |
|